Clinical Trial Update: Apixaban Evaluation of Interrupted Or Uninterrupted Anticoagulation for Ablation of Atrial Fibrillation [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating interrupted or uninterrupted anticoagulation with apixaban during atrial fibrillation ablation has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation

Drugs mentioned

• Apixaban (apixaban)

Snippet

Sponsor: Baim Institute for Clinical Research | Conditions: Atrial Fibrillation | Phase 4 | Status: COMPLETED | Results posted: 2020-03-17